Morgan Stanley Downgrades Amicus, Immunocore, and Immuneering: Biotech Stocks Tumble
Morgan Stanley downgrades Amicus, Immunocore, and Immuneering, sending biotech stocks tumbling. The report cites concerns over future growth prospects, impacting investor confidence and highlighting the importance of strong clinical data.
Morgan Stanley Downgrades Amicus, Immunocore, and Immuneering: Biotech Stocks Tumble Read More »